Study on Outcomes of Severe Cerebral and Disseminated Toxoplasmosis in Intensive Care Using PCR Diagnosis

What this Trial Is About

Toxoplasmosis is a common infection that can be severe enough to require intensive care, especially for people with weakened immune systems. This research aims to evaluate how different anti-infective treatments affect patients with severe forms of toxoplasmosis, including cerebral and disseminated types. It also seeks to identify clinical, biological, and prognostic differences based on the type of underlying immunosuppression in these patients. The study observes patients hospitalized in intensive care with confirmed toxoplasmosis diagnosed using polymerase chain reaction PCR tests from cerebrospinal fluid, blood, bronchoalveolar lavage, or bone marrow samples. It records the use of various treatment regimens such as oral pyrimethamine-sulfadiazine and intravenous treatments like trimethoprim-sulfamethoxazole or clindamycin combined with pyrimethamine. The study focuses on real-world management without altering treatments and includes patients with at least one organ failure. Participants will be monitored for outcomes including mortality rate in intensive care, hospital mortality, length of stay in intensive care, and duration of mechanical ventilation over an 11-year period. The study collects detailed clinical and biological information to better understand severe toxoplasmosis in immunocompromised patients. Data reuse is subject to patient consent, and the research is observational with no experimental interventions applied.

Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis